Literature DB >> 17400686

Sources of long-term variability in measurements of lung function: implications for interpretation and clinical trial design.

Robert L Jensen1, John G Teeter, Richard D England, Heather M Howell, Heather J White, Eve H Pickering, Robert O Crapo.   

Abstract

BACKGROUND: The objective of the study was to characterize the biological and technical components of variability associated with longitudinal measurements of FEV(1) and carbon monoxide diffusing capacity (Dlco). Variability was apportioned to subject and instrument for five commercially available pulmonary function testing (PFT) systems: Collins CPL (Ferraris Respiratory; Louisville, CO); Morgan Transflow Test PFT System (Morgan Scientific; Haverhill, MA); SensorMedics Vmax 22D (VIASYS Healthcare; Yorba Linda, CA); Jaeger USA Masterscreen Diffusion TP (VIASYS Healthcare; Yorba Linda, CA); and Medical Graphics Profiler DX System (Medical Graphics Corporation; St. Paul, MN).
METHODS: This was a randomized, replicated cross-over, single-center methodology study in 11 healthy subjects aged 20 to 65 years. Spirometry and Dlco measurements were performed at baseline, 3 months, and 6 months. Repetitive simulations of FEV(1) and Dlco were performed on the same instruments on four occasions over a 90-day period using a spirometry waveform generator and a Dlco simulator.
RESULTS: The coefficient of variation associated with repetitive measurements of FEV(1) or Dlco in subjects was consistently larger than that associated with repetitive simulated waveforms across the five instruments. Instrumentation accounted for 13 to 58% of the total FEV(1) and 36 to 70% of the total Dlco variability observed in subjects. Sample size estimates of hypothetical studies designed to detect treatment group differences of 0.050 L in FEV(1) and 0.5 mL/min/mm Hg in Dlco varied as much as four times depending on the instrument utilized.
CONCLUSIONS: These results provide a semiquantitative assessment of the biological and technical components of PFT variability in a highly standardized setting. They illustrate how instrument choice and test variability can impact sample size determinations in clinical studies that use FEV(1) and Dlco as end points.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400686     DOI: 10.1378/chest.06-1999

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Dawning of a new lung age?

Authors:  Brendan Cooper
Journal:  Prim Care Respir J       Date:  2012-03

2.  Reply: Decline of Lung Function in Children with Sickle Cell Disease Is Not Associated with Restrictive Defects.

Authors:  Robyn T Cohen; Mark Rodeghier; Michael R DeBaun
Journal:  Ann Am Thorac Soc       Date:  2017-03

3.  Age is a predictor of a small decrease in lung function in children with sickle cell anemia.

Authors:  Shaina M Willen; Robyn Cohen; Mark Rodeghier; Fenella Kirkham; Susan S Redline; Carol Rosen; Jane Kirkby; Michael R DeBaun
Journal:  Am J Hematol       Date:  2018-01-25       Impact factor: 10.047

Review 4.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Authors:  Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea
Journal:  Respir Res       Date:  2009-04-22

5.  Simulation system for a rebreathing technique to measure multiple cardiopulmonary function parameters.

Authors:  Cuneyt Yilmaz; William W Chance; Robert L Johnson; Connie C W Hsia
Journal:  Chest       Date:  2009-05       Impact factor: 9.410

Review 6.  Alzheimer's disease drug development: old problems require new priorities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-12       Impact factor: 4.388

7.  Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease.

Authors:  Michael B Drummond; Pamela F Schwartz; William T Duggan; John G Teeter; Richard J Riese; Richard C Ahrens; Robert O Crapo; Richard D England; Neil R Macintyre; Robert L Jensen; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2008-05-08       Impact factor: 21.405

8.  Smallest detectable change in volume differs between mass flow sensor and pneumotachograph.

Authors:  Herman Groepenhoff; Caroline B Terwee; Patrick Mc Jak; Anton Vonk-Noordegraaf
Journal:  BMC Res Notes       Date:  2011-01-28

9.  Symptoms and lung function decline in a middle-aged cohort of males and females in Australia.

Authors:  Michael J Abramson; Sonia Kaushik; Geza P Benke; Brigitte M Borg; Catherine L Smith; Shyamali C Dharmage; Bruce R Thompson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-05-26

10.  Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes.

Authors:  Julio Rosenstock; William T Cefalu; Priscilla A Hollander; Andre Belanger; Freddy G Eliaschewitz; Jorge L Gross; Solomon S Klioze; Lisa B St Aubin; Howard Foyt; Masayo Ogawa; William T Duggan
Journal:  Diabetes Care       Date:  2008-06-05       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.